EAM
SYRE icon

EFG Asset Management’s Spyre Therapeutics SYRE Stock Holding History

EFG Asset Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-82,472
Closed -$1.33M – 187
2025
Q1 		$1.33M Sell
82,472
-346
-0.4% -$7.2K 0.22% 162
2024
Q4 		$1.93M Buy
82,818
+30,608
+59% +$898K 0.26% 157
2024
Q3 		$1.53M Buy
52,210
+15,429
+42% +$430K 0.26% 163
2024
Q2 		$869K Buy
36,781
+25,630
+230% +$865K 0.15% 186
2024
Q1 		$423K Buy
+11,151
New +$323K 0.07% 190

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

EFG Asset Management's SYRE Position: Q2 2025 in Review

EFG Asset Management sold out of Spyre Therapeutics (SYRE) in Q2 2025, closing a stake of 82,472 shares — an estimated $1.33M sold.

EFG Asset Management first reported a position in SYRE in Q1 2024 and held it in 5 quarters. The position peaked at $1.93M in Q4 2024. 129 funds tracked by Wall St. Rank hold SYRE as of Q2 2025.

  • EFG Asset Management reported no remaining Spyre Therapeutics position as of Q2 2025 after selling out during the quarter.
  • EFG Asset Management sold 82,472 Spyre Therapeutics shares in Q2 2025, an estimated $1.33M.
  • EFG Asset Management first reported a position in Spyre Therapeutics in Q1 2024 and held it in 5 quarters.
  • EFG Asset Management's Spyre Therapeutics position peaked at $1.93M in Q4 2024.
  • 129 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2025.

Based on EFG Asset Management's 13F filing for Q2 2025, filed 6 Aug 2025.